← Browse by Condition
Medical Condition

aml

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for aml sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — aml Clinical Trials

How many clinical trials are currently recruiting for aml?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for aml, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for aml?
aml research spans Phase 1 (4 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a aml clinical trial?
Eligibility criteria for aml trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
2
Top Sponsors
St. Jude Children's Research Hospital 1 trial
CERo Therapeutics Holdings, Inc. 1 trial
Peking University People's Hospital 1 trial
University of Colorado, Denver 1 trial
University Hospital Tuebingen 1 trial

Recruiting Clinical Trials

NCT03050268
Recruiting
Familial Investigations of Childhood Cancer Predisposition
Enrollment
1,500 pts
Location
United States
Sponsor
St. Jude Children's Research H...
View Trial →
NCT06834282 Phase 1
Recruiting
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Enrollment
18 pts
Location
United States
Sponsor
CERo Therapeutics Holdings, In...
View Trial →
NCT07617285 Phase 1
Recruiting
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Enrollment
27 pts
Location
China
Sponsor
Peking University People's Hos...
View Trial →
NCT05287568 Phase 1
Recruiting
CC-486 and Venetoclax for Acute Myeloid Leukemia
Enrollment
35 pts
Location
United States
Sponsor
University of Colorado, Denver
View Trial →
NCT06156579 Phase 2
Recruiting
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
Enrollment
27 pts
Location
Germany
Sponsor
University Hospital Tuebingen
View Trial →
NCT06420063 Phase 1, Phase 2
Recruiting
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Enrollment
85 pts
Location
China
Sponsor
Essen Biotech
View Trial →
NCT07490288
Recruiting
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
Enrollment
27 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →

Related Conditions

mds (2) acute myeloid leukemia (2) acute leukemia (1) adenomatous polyposis (1) adrenocortical carcinoma (1) bap1 tumor predisposition syndrome (1) carney complex (1) choroid plexus carcinoma (1) constitutional mismatch repair deficiency syndrome (1) diamond blackfan anemia (1) dicer1 syndrome (1) dyskeratosis congenita (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology